Audentes Therapeutics Inc (NASDAQ:BOLD) was down 4.2% on Thursday . The company traded as low as $14.50 and last traded at $14.99, with a volume of 56,348 shares trading hands. The stock had previously closed at $15.64.

A number of equities research analysts recently weighed in on BOLD shares. Piper Jaffray Cos. assumed coverage on Audentes Therapeutics in a report on Monday, August 15th. They set an “overweight” rating and a $24.00 price target for the company. Cowen and Company assumed coverage on Audentes Therapeutics in a research report on Monday, August 15th. They issued an “outperform” rating on the stock. Finally, Wedbush assumed coverage on Audentes Therapeutics in a research report on Monday, August 15th. They issued an “outperform” rating and a $20.00 price objective on the stock.

The stock’s market cap is $32.98 million. The company’s 50-day moving average price is $14.98 and its 200 day moving average price is $14.98.

In other news, Director Orbimed Advisors Llc acquired 33,334 shares of Audentes Therapeutics stock in a transaction dated Monday, July 25th. The stock was bought at an average price of $15.00 per share, for a total transaction of $500,010.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Versant Ventures Iv, Llc acquired 35,000 shares of Audentes Therapeutics stock in a transaction dated Monday, July 25th. The shares were purchased at an average price of $15.00 per share, with a total value of $525,000.00. The disclosure for this purchase can be found here.

Audentes Therapeutics, Inc is a biotechnology company. The Company focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. Its portfolio of product candidates include AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.